166 related articles for article (PubMed ID: 12234859)
21. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Hoppe JE; Dalhoff A; Pfründer D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
[No Abstract] [Full Text] [Related]
22. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
Boswell FJ; Andrews JM; Wise R
J Antimicrob Chemother; 2001 Sep; 48(3):446-7. PubMed ID: 11533016
[No Abstract] [Full Text] [Related]
23. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
[TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
Edlund C; Sabouri S; Nord CE
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility of anaerobic bacteria to PD 131628.
Nord CE; Hagelbäck A
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
[TBL] [Abstract][Full Text] [Related]
27. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
28. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
29. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
30. Emergence of fluoroquinolone resistance among Bacteroides species.
Golan Y; McDermott LA; Jacobus NV; Goldstein EJ; Finegold S; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Iannini P; Gorbach SL; Snydman DR
J Antimicrob Chemother; 2003 Aug; 52(2):208-13. PubMed ID: 12865399
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
32. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
[TBL] [Abstract][Full Text] [Related]
33. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Falagas ME; McDermott L; Snydman DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
[TBL] [Abstract][Full Text] [Related]
34. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
36. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
38. Time-kill studies of the activity of temafloxacin against four strains of Bacteroides.
Brown WJ; Moosavi S
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S355-6. PubMed ID: 8391863
[No Abstract] [Full Text] [Related]
39. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
